Company profile
Scilex Holding Company
NASDAQ: SCLX · Healthcare · Drug Manufacturers - General
#505 of 1,418 Healthcare companies by revenuebottom-quartile growth
EA Score
28DFH 26DQ 21GM 38SS 43
v0.1 · 65/100 weight · provisional
↑ growth stability, market scale · ↓ revenue growth (YoY), filing timeliness
Methodology →Revenue TTM
$31.6M
Rev growth YoY (TTM)
-28.5%
Net income (FY)
-$374.1M
Employees
34
as of 2026-08-19
Market cap
$53.8M
as of 2026-08-19
Financials — latest annual
SEC EDGAR · USD-normalizedConceptUSDNativeFY
Revenue$30.3M$30.3M2025
Net income-$374.1M-$374.1M2025
Operating income-$346.0M-$346.0M2025
Total assets$365.0M$365.0M2025
Liabilities$576.7M$576.7M2025
Equity-$207.8M-$207.8M2025
Revenue trend
FY2022 – FY2025 · USD
FY22
FY22
FY22
FY23
FY24
FY25
Revenue by segment
No segmentation disclosed for this filer. n/a
The read
What is Scilex Holding Company’s revenue?
Scilex Holding Company booked $30.3M in FY2025 revenue, contracting 47% year over year — slower than 80% of Healthcare companies we track, at a -1236.4% net margin.
Peers · Healthcare
STRATA Skin Sciences, Inc.52DYourWay Cannabis Brands Inc.——Synergy CHC Corp.35DDelota Corp.——IMRIS Inc.——Nanalysis Scientific Corp.59CNeighbors
Santa Clara →Key facts
CEOHenry H. Ji
SectorHealthcare
IndustryDrug Manufacturers - General
HeadquartersPalo Alto, CA
ExchangeNASDAQ: SCLX
Employees34
IPO date2021-03-05
Financials: SEC EDGAR (XBRL), USD-normalized per IAS 21 · TTM/quarterly + segments: FMP from filed disclosures · Filings: EDGAR submissions. County headcount and EA Score are in progress — see docs/DATA_GAPS.md.